Cabozantinib is the first generation targeted drug

Cabozantinib is a third-generation targeted drug and a broad-spectrum target drug. Cabozantinib inhibits MET and VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KI Tyrosine kinase activities of T, TRKB, FLT-3, and TIE-2.

Cabozantinib is indicated for the treatment of progressive metastatic medullary thyroid carcinoma(MTC), and is indicated for the first-line treatment of advanced renal cell carcinoma(RCC) in combination with nivolumab. Applicable to Hepatocellular Carcinoma(HCC) patients who have previously received sorafenib treatment. Applicable to adults with locally advanced or metastatic differentiated thyroid cancer that has progressed after previous VEGFR targeted therapy(DTC )and adults who are refractory or ineligible for radioactive iodine.

After taking cabozantinib orally, the median time to peak plasma concentration of cabozantinib is 2-5 hours. Cabometyxis 3-4 hours. After a single dose of 140 mg cabozantinib capsules or tablets, peak plasma concentrations were 19% higher for cabozantinib tablets than cabozantinib capsules; however, a AUCdifference of < 10% was observed between the tablet and capsule formulations. The concentration reached within days after taking cabozantinib capsules at steady state. Take with a high-fat mealThe 140 mg dose of cabozantinib increased peak concentration and AUC relative to fasted conditions by 41% and 57% decreased, respectively. Population pharmacokinetic analysis showed no clinically important differences in cabozantinib exposure between patients with normal hepatic function and patients with mild hepatic impairment. In a pharmacokinetic study, cabozantinib exposure was increased by 63% in patients with moderate hepatic impairment. Patients with severe hepatic impairment have not been studied. Systemic exposure to cabozantinib (Cabometyx) in pediatric patients ≥ 12 years of age is expected to be equivalent to adult exposure at the recommended dose of 60 mg once daily. Laos ASEAN Pharmaceuticals, United Pharmaceuticals, Lucius Pharmaceuticals, Element Pharmaceuticals, etc. are produced, and the cost per box is less than 20mg*90 capsules1,000 yuan. The retail price of Everest Pharmaceuticals, Yaopin International and Beacon Pharmaceuticals in Bangladesh is around 20mg*90 capsules 2000 per box. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.